NRx Pharmaceuticals, Inc.
NASDAQ:NRXPBiotechnology
+$0.06 today
- Market cap
- $124.12M
- Beta
- 2.19
- P/E (TTM)
- -5.3
- EPS (TTM)
- -$0.76
Volume 2.09M
Average 1.27M
NRXP Total Current Liabilities
All obligations due within one year.
NRx Pharmaceuticals, Inc.NASDAQ: NRXP
Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total current liabilities falls 23.1% from a year ago
Total current liabilities stood at $25.18M at the end of Q1 FY2026, down 23.1% from a year earlier and down 11.9% from the prior quarter. Over 3 fiscal years it compounded at +22.4% a year.
Context
- Total current liabilities amounted to 211.5% of total assets at the end of Q1 FY2026, down 220.0 pp from a year earlier.
- Total current liabilities increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current liabilities keeps falling in the next quarterly balance sheet after a -23.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 28.58M USD
- Year-over-year change
- +30.7%
- 4-year CAGR
- +24.4%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 28.58M | +30.7% |
| FY2024 | 2024-12-31 | 21.86M | +14.8% |
| FY2023 | 2023-12-31 | 19.05M | +22.2% |
| FY2022 | 2022-12-31 | 15.59M | +30.7% |
| FY2021 | 2021-12-31 | 11.92M | — |
Total Current Liabilities vs competitors
How NRXP compares with its peers on the latest reported figures
- NRXP's Mar 2026 total current liabilities of $25.18M is the 3rd highest of the 9 companies compared; the peer median is $9.82M.
- Its year-over-year change of -23.1% is the 4th highest of 9, against a peer median of -34.5%.
- Total current liabilities amounts to 211.5% of total assets for NRXP, versus a peer median of 22.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $117.3M | +29.8% | +11.8% | 89.3% | |
| Mar 2026 | $38.88M | +56.6% | +32.4% | 177.6% | |
| Mar 2026 | $25.18M | -23.1% | +22.4% | 211.5% | |
| Mar 2026 | $13.57M | -6.5% | -12.1% | 4.2% | |
| Mar 2026 | $11.78M | -24.8% | -6.8% | 21.0% | |
| Jun 2026 | $7.86M | -48.2% | +14.6% | 32.6% | |
| Mar 2026 | $7.39M | -52.3% | +5.3% | 23.9% | |
| Mar 2026 | $3.35M | -44.3% | -54.9% | 5.3% | |
| Mar 2026 | $1.82M | -67.8% | -6.6% | 9.2% | |
| Peer median (excluding NRXP) | $9.82M | -34.5% | -0.7% | 22.5% | |
Competitors are the stored peer set for NRXP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
NRx Pharmaceuticals, Inc.
NASDAQ:NRXP
Intrinsic Alpha fair value
Locked
Current Price
$2.80
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.